Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies

Autor: R. V. Kholodenko, Elena V. Svirshchevskaya, Maria Konovalova, Tatyana V. Shamanskaya, Sergey S. Larin, Igor Doronin, Alexey V. Kibardin, I. V. Kholodenko, Daniel V. Kalinovsky, Sergey M. Deyev
Jazyk: angličtina
Rok vydání: 2019
Předmět:
medicine.medical_treatment
ganglioside GD2
Pharmaceutical Science
Article
Analytical Chemistry
Polyethylene Glycols
lcsh:QD241-441
03 medical and health sciences
neuroblastoma
Mice
0302 clinical medicine
Antineoplastic Agents
Immunological

lcsh:Organic chemistry
Pharmacokinetics
Neuroblastoma
Cell Line
Tumor

Gangliosides
Drug Discovery
medicine
Cytotoxic T cell
multimerization
cancer
Animals
Humans
pegylation
Physical and Theoretical Chemistry
030304 developmental biology
0303 health sciences
antibody fragments
Mice
Inbred BALB C

Ganglioside
biology
Chemistry
Organic Chemistry
Immunotherapy
Neoplasms
Experimental

medicine.disease
Biochemistry
Chemistry (miscellaneous)
030220 oncology & carcinogenesis
biology.protein
PEGylation
Molecular Medicine
immunotherapy
Antibody
Conjugate
Single-Chain Antibodies
Zdroj: Molecules
Molecules, Vol 24, Iss 21, p 3835 (2019)
Volume 24
Issue 21
ISSN: 1420-3049
Popis: Antigen-binding fragments of antibodies specific to the tumor-associated ganglioside GD2 are well poised to play a substantial role in modern GD2-targeted cancer therapies, however, rapid elimination from the body and reduced affinity compared to full-length antibodies limit their therapeutic potential. In this study, scFv fragments of GD2-specific antibodies 14.18 were produced in a mammalian expression system that specifically bind to ganglioside GD2, followed by site-directed pegylation to generate mono-, di-, and tetra-scFv fragments. Fractionated pegylated dimers and tetramers of scFv fragments showed significant increase of the binding to GD2 which was not accompanied by cross-reactivity with other gangliosides. Pegylated multimeric di-scFvs and tetra-scFvs exhibited cytotoxic effects in GD2-positive tumor cells, while their circulation time in blood significantly increased compared with monomeric antibody fragments. We also demonstrated a more efficient tumor uptake of the multimers in a syngeneic GD2-positive mouse cancer model. The findings of this study provide the rationale for improving therapeutic characteristics of GD2-specific antibody fragments by multimerization and propose a strategy to generate such molecules. On the basis of multimeric antibody fragments, bispecific antibodies and conjugates with cytotoxic drugs or radioactive isotopes may be developed that will possess improved pharmacokinetic and pharmacodynamic properties.
Databáze: OpenAIRE
Nepřihlášeným uživatelům se plný text nezobrazuje